Updates are available Correction dated 2026-05-20
Click to view Correction: https://doi.org/10.1186/s13195-026-02072-x
-
Authors
Xia, Xin
Clark, Alice
Brogaard, Niels Juul
Mourer, Alex
Areovimata, Anna
Eriksdotter, Maria
Zetterberg, Henrik
Kern, Silke
Skillbäck, Tobias
Jönsson, Linus
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 2 July 2025
First Online: 12 July 2025
Change Date: 12 May 2026
Change Type: Update
Change Details: The original article was revised: some numbers under column “No. events/No. people at risk” in Table 3 are shown as months.
Change Date: 20 May 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-026-02072-x
Declarations
:
: The study received approval from the Swedish Ethical Review Authority (DNR: 2023-06581-02). Written consent was not necessary for this study, as the study is a national register-based study. However, patients have been informed about the registration and have the right to decline to be registered in SveDem.
: Maria Eriksdotter has served as a consultant for Roche, Biogen, Bioarctic, Lilly and Novo Nordisk A/S and has given lectures in symposia sponsored by Roche. Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator. Silke Kern has served on scientific advisory boards, speaker and/or consultant for Roche, Geras Solutions, Optoceutics, Eli Lilly, Biogen, Novo Nordisk A/S, Merry Life, Triolab and Bioarctic. Linus Jönsson has received consulting fees from H. Lundbeck A/S, Novo Nordisk A/S and TEVA Inc, and license fees for the Resource Utilization in Dementia (RUD) instrument. Others report no conflicts of interest pertinent to this work.
